Cancer that has spread to the bones is one of the complications of pancreatic cancer. However, a new drug has been developed that has been found to slow down the spread of cancer in bones in prostate cancer patients, reports a new study published in the Lancet.
The Food and Drug Administration has approved the drug called Denosumab for the prevention of fractures and osteoporosis with bone metastases with solid tumors. Now researchers think that Denosumab can help delay the progression of prostate cancer spread to the bones. Cancer spread to the bones is one of the most common sites for which prostate cancer spreads.
This is an encouraging report, considering that patients who have prostate cancer that has spread to the bone can have a poor outcome, so its metastasis to the bones prevention is key to a more favorable outcome.
The study examined 1,400 patients across 30 countries. Patients were assigned randomly to receive drug injections or a placebo over a two-year study timeframe. The injection was given every month. During the two-year period, patient underwent skeletal surveys and bone scans to determine if metastases was present.
The results of the study indicated that Denosumab increased bone-free metastasis on average of four months longer than those on the placebo. This treatment is the first of its kind to delay metastases without the use of chemotherapy or hormone treatment.
All-in-all, four new drugs have been have been developed within the last year to help treat prostate cancer patients. What's more new treatments have evolved to treat the disease, including vaccine therapy as well as chemotherapy to treat more advanced stages of prostate cancer.